Twelve‐month safety and effectiveness of TCD‐17187 drug‐coated balloon for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery

The aim of this preapproval trial was to evaluate the 12‐month safety and effectiveness of the TCD‐17187 drug‐coated balloon (DCB) for the treatment of atherosclerotic lesions in the superficial femoral artery (SFA) and/or proximal popliteal artery (PA).

[1]  M. Brodmann,et al.  Delphi Consensus Study Toward a Comprehensive Classification System for Angioplasty-Induced Femoropopliteal Dissection: The DISFORM Study. , 2021, JACC. Cardiovascular interventions.

[2]  Shuofei Yang,et al.  One-Year Clinical Outcome and Risk Factor Analysis of Directional Atherectomy Followed With Drug-Coated Balloon for Femoropopliteal Artery Disease , 2021, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[3]  M. Brodmann,et al.  1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon. , 2021, JACC. Cardiovascular interventions.

[4]  M. Fujihara,et al.  A Novel Angiographic Risk Score for Femoropopliteal Interventions , 2020, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[5]  D. Scheinert,et al.  COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions , 2020, European heart journal.

[6]  A. AbuRahma,et al.  Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease: A real-world single-center experience. , 2019, Journal of vascular surgery.

[7]  H. Garcia-Garcia,et al.  Letter by Dan et al Regarding Article, "Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial". , 2018, Circulation. Cardiovascular interventions.

[8]  Hong Wang,et al.  Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial , 2017, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[9]  P. Faries,et al.  Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease , 2017, Circulation.

[10]  A. Kastrati,et al.  Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. , 2016, JACC. Cardiovascular interventions.

[11]  H. Yokoi,et al.  1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis. , 2015, JACC. Cardiovascular interventions.

[12]  A. Cannavale,et al.  Calcium Burden Assessment and Impact on Drug-Eluting Balloons in Peripheral Arterial Disease , 2014, CardioVascular and Interventional Radiology.

[13]  P. Krishnan,et al.  Effective Endovascular Treatment of Calcified Femoropopliteal Disease With Directional Atherectomy and Distal Embolic Protection: Final Results of the DEFINITIVE Ca++ Trial , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  Igor Rudan,et al.  Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.

[15]  M. Nobuyoshi,et al.  Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. , 2010, Journal of vascular surgery.

[16]  Thomas Zeller,et al.  Current state of endovascular treatment of femoro-popliteal artery disease , 2007, Vascular medicine.

[17]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[18]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.